Since EMT is a hallmark of castration resistance, cancer stem cells generation, chemoresistance and worse prognosis for prostate cancer, targeting DNMT3A may be of great therapeutic value in improving the prognosis of advanced and metastatic prostate cancer. Here, DNMT3A is linked to cancer.